Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9, 21-23
eCollection

Initial Second-Line Drug Resistance of Mycobacterium tuberculosis Isolates From Sudanese Retreatment-Patients

Affiliations

Initial Second-Line Drug Resistance of Mycobacterium tuberculosis Isolates From Sudanese Retreatment-Patients

Muatsim Ahmed Mohammed Adam et al. J Clin Tuberc Other Mycobact Dis.

Abstract

Setting: Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are a major public health threat.

Objective: This study aimed to determine resistance patterns to second line anti-TB drugs (SLDs), and to determine the frequency of extensively drug resistant Mycobacterium tuberculosis (XDR-TB).

Design: During the period from July 2009 to July 2010; sputum specimens were collected from TB retreatment patients; isolates were tested for sensitivity to first line anti-TB drugs by the 1% proportion method; MDR strains were tested for second line anti-TB drugs sensitivity by 1% proportion method and by version 1. Hain GenoType MTBDRsl Assay.

Results: One hundred and forty three mycobacterial isolates were successfully recovered from a total of 239 specimens (143/239; 59.8%). Fifty six strains were rifampicin resistant (RR); of these 54 were multi-drug resistant (MDR); two were RIF/INH-resistant mycobacterium other than tuberculosis (MOTT). Five of MDR (5/50; 10%) showed resistance to at least one second line drug and one isolate (1/50; 2%) was XDR. The XDR strain was concordantly detected by the two methods.

Conclusion: Initial resistance to second line anti-TB drugs among MDR-TB patients is at 10% levels and XDR-TB is prevalent at low levels (2%). Nevertheless; without great efforts from national tuberculosis control program (NTP) this figure can fuel the TB epidemics in Sudan.

Keywords: Pre –XDR; SLDs; Sudan; XDR-TB.

Similar articles

See all similar articles

References

    1. World Health Organization . Vol. 22. 2015. (Global tuberculosis report WHO/HTM/TB/2015). Geneva, Switzerland www.who.int.
    1. Gandhi N.R., Moll A., Sturm A.W., Pawinski R., Govender T., Lalloo U. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575–1580. http://DOI:10.1016/S0140-6736(06)69573-1 - DOI - PubMed
    1. Selvakumar N., Kumar V., Balaji S., Prabuseenivasan S., Radhakrishnan R., Sekar G. High rates of ofloxacin resistance in mycobacterium tuberculosis among both new and previously treated patients in Tamil Nadu, South India. PLoS ONE. 2015;10(3) doi: 10.1371/journal.pone.0117421. doi: - DOI - PMC - PubMed
    1. Sotgiu G., Ferrara G., Matteelli A., Richardson M.D., Centis R., Ruesch-Gerdes S. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009;33:871–888. - PubMed
    1. Singhal P., Dixit P., Singh P., Jaiswal I., Singh M., Jain A. A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India Indian. J Med Res. 2016;143(March):341–347. http://DOI:10.4103/0971-5916.182625. - DOI - PMC - PubMed
Feedback